EVMN
NYSE HealthcareEvommune, Inc. Common Stock
Biotechnology
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.
๐ Market Data
| Price | $8.40 |
|---|---|
| Volume | 245,727 |
| Market Cap | 304.49M |
| RSI (14-Day) | 20.0 Oversold |
| 200-Day MA | $19.32 |
| 50-Day MA | $12.17 |
| 52-Week High | $33.20 |
| 52-Week Low | $8.38 |
| Forward P/E | -2.44 |
| Price / Book | 1.10 |
๐ฏ Investment Strategy Scores
EVMN scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (98/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Institutional Whale (3/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find EVMN in your text
Paste any article, transcript, or post โ the tool will extract EVMN and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-09-24.